WEKO3
アイテム
Potential utility of novel tau PET ligand, 18F-PM-PBB3
https://repo.qst.go.jp/records/72716
https://repo.qst.go.jp/records/72716f378e698-3003-4f53-9d8a-181dc2b2c2b0
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-03-22 | |||||
| タイトル | ||||||
| タイトル | Potential utility of novel tau PET ligand, 18F-PM-PBB3 | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
島田, 斉
× 島田, 斉× 島田 斉 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background and Aims: 11C-PBB3 is a tau PET ligand that can visualize diverse tau pathologies including Alzheimer’s disease (AD), non-AD tauopathies, and tau transgenic mice. We have developed a 18F-labeled PBB3 derivative, 18F-PM-PBB3. To evaluate the potential utility of this ligand in clinical trials of tau targeting agents, we conducted preclinical and clinical studies using 18F-PM-PBB3. Methods: Preclinical characterization of 18F-PM-PBB3 was performed using brain samples of humans and model mice. To perform head-to-head comparison between 18F-PM-PBB3 and 11C-PBB3, patients with AD and progressive supranuclear palsy (PSP), and cognitively healthy subjects underwent PET scans with 18F-PM-PBB3 and 11C-PBB3. Results: Preclinical evaluations demonstrated that 18F-PM-PBB3 can bind diverse tau pathologies, including AD, PSP, corticobasal degeneration and Pick’s disease, with high sensitivity and specificity. In clinical PET study, dynamic ranges of 18F-PM-PBB3 yield about 2-fold higher than 11C-PBB3 in visualizing tau lesions, while distribution patterns of specific binding are similar. 18F-PM-PBB3 does not produce prominent off-target signals in basal ganglia. Standardized uptake value ratios can be used as robust and simplified indices of the specific binding. Conclusions: 18F-PM-PBB3 is a promising PET ligand for quantifying tau pathologies in AD and non-AD patients with suitable pharmacokinetics and high contrast. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 13th Annual Biomarkers Congress | |||||
| 発表年月日 | ||||||
| 日付 | 2017-02-15 | |||||
| 日付タイプ | Issued | |||||
